These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen. Tabouret E; Barrie M; Thiebaut A; Matta M; Boucard C; Autran D; Loundou A; Chinot O J Neurooncol; 2013 Sep; 114(2):191-8. PubMed ID: 23756726 [TBL] [Abstract][Full Text] [Related]
3. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab. Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555 [TBL] [Abstract][Full Text] [Related]
4. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Piccioni DE; Selfridge J; Mody RR; Chowdhury R; Li S; Lalezari S; Wawrzynski J; Quan J; Zurayk M; Chou AP; Sanchez DE; Liau LM; Ellingson BM; Pope WB; Nghiemphu PL; Green RM; Wang HJ; Yong WH; Elashoff R; Cloughesy TF; Lai A Neuro Oncol; 2014 Jun; 16(6):815-22. PubMed ID: 24627236 [TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic therapy for high-grade glioma. Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542 [TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma. Arakawa Y; Mizowaki T; Murata D; Fujimoto K; Kikuchi T; Kunieda T; Takahashi JC; Takagi Y; Miyamoto S Neurol Med Chir (Tokyo); 2013; 53(11):779-85. PubMed ID: 24140770 [TBL] [Abstract][Full Text] [Related]
7. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. Hamza MA; Mandel JJ; Conrad CA; Gilbert MR; Yung WK; Puduvalli VK; DeGroot JF J Neurooncol; 2014 Aug; 119(1):135-40. PubMed ID: 24803001 [TBL] [Abstract][Full Text] [Related]
8. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Nayak L; Molinaro AM; Peters K; Clarke JL; Jordan JT; de Groot J; Nghiemphu L; Kaley T; Colman H; McCluskey C; Gaffey S; Smith TR; Cote DJ; Severgnini M; Yearley JH; Zhao Q; Blumenschein WM; Duda DG; Muzikansky A; Jain RK; Wen PY; Reardon DA Clin Cancer Res; 2021 Feb; 27(4):1048-1057. PubMed ID: 33199490 [TBL] [Abstract][Full Text] [Related]
9. The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas. Kaloshi G; Diamandi P; Cakani B; Brace G; Rroji A; Petrela M Tumori; 2015; 101(1):41-5. PubMed ID: 25702676 [TBL] [Abstract][Full Text] [Related]
10. Implications of bevacizumab discontinuation in adults with recurrent glioblastoma. Anderson MD; Hamza MA; Hess KR; Puduvalli VK Neuro Oncol; 2014 Jun; 16(6):823-8. PubMed ID: 24596117 [TBL] [Abstract][Full Text] [Related]
11. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. Dirven L; van den Bent MJ; Bottomley A; van der Meer N; van der Holt B; Vos MJ; Walenkamp AM; Beerepoot LV; Hanse MC; Reijneveld JC; Otten A; de Vos FY; Smits M; Bromberg JE; Taal W; Taphoorn MJ; Eur J Cancer; 2015 Jul; 51(10):1321-30. PubMed ID: 25899986 [TBL] [Abstract][Full Text] [Related]
12. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291 [TBL] [Abstract][Full Text] [Related]
13. Bevacizumab alone at 5 mg/kg in an every-3-week schedule for patients with recurrent glioblastomas: a single center experience. Kaloshi G; Brace G; Rroji A; Bushati T; Roci E; Hoxha M; Fejzo G; Petrela M Tumori; 2013; 99(5):601-3. PubMed ID: 24362864 [TBL] [Abstract][Full Text] [Related]
14. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab. Zhong J; Ali AN; Voloschin AD; Liu Y; Curran WJ; Crocker IR; Shu HK Cancer; 2015 May; 121(9):1456-62. PubMed ID: 25557543 [TBL] [Abstract][Full Text] [Related]